In a novel ABO-incompatible kidney transplantation, investigators converted the deceased donor kidney’s blood type.

Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to ...

Dr. MacBeath continued, "We have a unique opportunity to develop ... trial. The Company plans to expand HLA coverage of the heme program with two additional investigational new drug (IND) applications ...

Urolithin A, a natural postbiotic known to trigger mitophagy, rejuvenated key immune cell functions in healthy middle-aged ...